Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Carl Zeiss Microscopy’s Axio Lab.A1 microscope is available for use in polarization microscopy. It is suitable for student education and routine laboratory requirements. This upright microscope suits colleges and universities, research institutes in the geosciences and mineralogy fields, and in the oil exploration industry.
Hamilton Robotics’ PCR setup Starlet automated liquid-handling system can accommodate any DNA amplification reagent kit, from simple setups and small budgets to highly demanding workflows. The workstation is suitable for gene expression, genotyping, sequencing, or mutagenesis. It was developed for different PCR types, such as endpoint-, q-, multiplex, or linear PCR.
CellaVision and Beckman Coulter have added Europe, the Middle East, and Africa to their global distribution agreement. The agreement gives Beckman Coulter a nonexclusive right to sell CellaVision’s products in hematology laboratories worldwide, except in Canada and Japan. Beckman and CellaVision have been developing their partnership since 2010, when they partnered in the United States, Latin America, and Asia-Pacific, including in China and India.
Thermo Fisher Scientific’s iCAP 7000 series ICP-OES (inductively coupled plasma optical emission spectrometer) is driven by Qtegra Intelligent Scientific Data Solution (ISDS) software. The platform, designed to streamline workflows and minimize cost per sample, facilitates trace elemental analysis in pharmaceutical, environmental, industrial, and food and beverage analysis applications.
Hardy Diagnostics’ parasite suspensions are designed for a variety of parasitology applications to provide reliable and consistent quality control results. The suspensions are microorganism preparations designed to mimic patient samples to support quality assurance programs in documenting process and detection proficiency. The suspensions can be used in the QC or validation of diagnostic test kits and methods, in microscopic examinations, in staining procedures, in proficiency testing, and for teaching purposes in educational settings.
Abbott has introduced in the European Union and other areas outside of the United States a molecular diagnostic test for the detection of influenza A/B and RSV (respiratory syncytial virus). The IMDx flu A/B and RSV assay, developed by Intelligent Medical Devices for Abbott’s m2000 molecular diagnostics analyzer, is performed on nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. It is a qualitative, reverse-transcription polymerase chain reaction test for rapid detection of influenza A/B and RSV.
SciGene and BioDot have entered into an agreement whereby BioDot would have exclusive rights to market and sell SciGene’s Little Dipper Processor for fluorescence in situ hybridization to cytogenetic labs worldwide. The instrument automates tissue and cell sample processing for a variety of cytogenetic tests. Terms of the deal were not disclosed.
Athena Diagnostics offers new genetic tests to aid in the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy, and certain movement disorders. The lab-developed tests are available through Athena, a business of Quest Diagnostics.
Illumina’s TruSight Tumor, for NGS-based somatic variant detection in solid tumors, provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.
Bio SB, through its partnership with ZytoVision of Germany, can now distribute a complete line of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas. The line of lung carcinoma CISH and FISH probes includes ZytoLight ALK/EML4 Tricheck triple-color probe (Z-2144-200), ZytoDot EGFR/CEN7 dual-color probe (C-3033-400), and many more.
